Current use of dietary supplementation in patients with age-related macular degeneration
- PMID: 12608514
- DOI: 10.1016/s0008-4182(03)80005-4
Current use of dietary supplementation in patients with age-related macular degeneration
Abstract
Background: The Age-Related Eye Disease Study (AREDS) Research Group recently reported significant reduction in the progression of certain categories of age-related macular degeneration (AMD) with the use of high-dose antioxidant and zinc supplementation. We studied the current use of dietary supplementation in our patients with AMD to determine whether dosages recommended in the AREDS were being achieved. We also evaluated the easiest and most cost-effective method to reach recommended dosages using supplements currently available in Canada.
Methods: Cross-sectional descriptive study conducted by patient survey from Feb. 1 to Mar. 31, 2002. All patients with the diagnosis of AMD were surveyed during an office visit at a retinal specialty clinic in Edmonton. The following information was collected: demographic information, duration of AMD, smoking status and current use of dietary supplements. For patients using supplements, we also noted duration of use, reason for use, who recommended use, and type and dosage of supplements (including vitamin, mineral and herbal supplements). The exact dosages were confirmed by follow-up telephone interview. Cost estimates were determined by averaging retail prices from several local pharmacies. We compared methods of reaching the recommended dosages using various combinations of commercially available multivitamin formulations and individual beta-carotene, vitamin C and E, and zinc supplements. The goal was to match the dosage recommended in the AREDS (without exceeding it if possible) at maximum convenience and minimum cost and without increasing the risk of toxic effects.
Results: Of 108 patients with AMD surveyed, 85 (79%) were taking dietary supplements, and 73 (68%) were taking at least one AREDS ingredient. The mean dosages of beta-carotene, vitamins C and E, and zinc were all below those recommended in the AREDS. None of our patients met the recommended dosages for all four ingredients. We identified four methods of reaching recommended dosages using various combinations of ICAPS TR, Ocuvite and Vitalux as well as Centrum multivitamin and individual supplements.
Interpretation: Patients with AMD may not be receiving the dosages of beta-carotene, vitamins C and E, and zinc recommended in the AREDS. Until new formulations of high-dose antioxidant and zinc supplements are available in Canada, patients should be counselled to attempt to meet recommended dosages by using combinations of currently available supplements.
Similar articles
-
A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.Arch Ophthalmol. 2001 Oct;119(10):1417-36. doi: 10.1001/archopht.119.10.1417. Arch Ophthalmol. 2001. PMID: 11594942 Free PMC article. Clinical Trial.
-
Adherence to recommendations of the age-related eye disease study in patients with age-related macular degeneration.Retina. 2010 Sep;30(8):1166-70. doi: 10.1097/IAE.0b013e3181cea5c6. Retina. 2010. PMID: 20827137
-
CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration.Ophthalmology. 2013 Nov;120(11):2317-23. doi: 10.1016/j.ophtha.2013.07.039. Epub 2013 Aug 21. Ophthalmology. 2013. PMID: 23972322 Clinical Trial.
-
Age-related macular degeneration and nutritional supplementation: a review of randomised controlled trials.Ophthalmic Physiol Opt. 2003 Sep;23(5):383-99. doi: 10.1046/j.1475-1313.2003.00130.x. Ophthalmic Physiol Opt. 2003. PMID: 12950886 Review.
-
Nutritional supplements in age-related macular degeneration.Acta Ophthalmol. 2015 Mar;93(2):105-21. doi: 10.1111/aos.12650. Epub 2015 Jan 13. Acta Ophthalmol. 2015. PMID: 25586104 Review.
Cited by
-
A qualitative exploration of Australian eyecare professional perspectives on Age-Related Macular Degeneration (AMD) care.PLoS One. 2020 Feb 11;15(2):e0228858. doi: 10.1371/journal.pone.0228858. eCollection 2020. PLoS One. 2020. PMID: 32045445 Free PMC article.
-
Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges.Pharmacoeconomics. 2016 Mar;34(3):259-72. doi: 10.1007/s40273-015-0347-y. Pharmacoeconomics. 2016. PMID: 26563248 Review.
-
Patients' knowledge and perspectives on wet age-related macular degeneration and its treatment.Clin Ophthalmol. 2010 May 6;4:375-81. doi: 10.2147/opth.s9969. Clin Ophthalmol. 2010. PMID: 20463907 Free PMC article.
-
Patient Use of Dietary Supplements, Home Monitoring, or Genetic Testing for Nonneovascular Age-Related Macular Degeneration.J Vitreoretin Dis. 2021 Apr 26;5(5):389-395. doi: 10.1177/2474126421989228. eCollection 2021 Sep-Oct. J Vitreoretin Dis. 2021. PMID: 37008702 Free PMC article.
-
Is complementary and alternative medicine (CAM) cost-effective? A systematic review.BMC Complement Altern Med. 2005 Jun 2;5:11. doi: 10.1186/1472-6882-5-11. BMC Complement Altern Med. 2005. PMID: 15932647 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous